Stock Information IR & ESG STOCK INFORMATION STOCK PRICE AND CHART SHAREHOLDER STRUCTURE FINANCIAL ANALYSTS DIVIDEND FINANCIALS PUBLICATIONS NEWS IR & ESG EVENTS ANNUAL GENERAL MEETING ESG ESG PERFORMANCE & REPORTING ENVIRONMENT SOCIAL GOVERNANCE CONTACT IR & ESG In this section you will find detailed information regarding the Evotec SE share, ranging from basic share data over stock charts, shareholder structure, our financial analysts, our auditors to our dividend policy. BASIC SHARE DATA Listing on Frankfurt Stock Exchange (XETRA) Listing NASDAQ, New York Security identification numbers Ordinary bearer shares ISIN: DE0005664809 American Depositary Shares (“ADSs”) ISIN: US30050E1055 Ticker symbol Frankfurt Stock Exchange: EVT NASDAQ: EVO Bloomberg Xetra: EVT GY Equity Reuters Xetra: EVTG.DE Stock exchange Frankfurt Stock Exchange NASDAQ New York Segment Prime Standard Global Select Market Index MDAX, TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX n/a Designated Sponsor ODDO SEYDLER BANK AG Paying agent Deutsche Bank AG, Frankfurt am Main J.P. Morgan Number of shares issued 175,412,241 ordinary bearer shares 20,000,000 ADSs (10,000,000 ordinary shares) Nominal capital € 175,412,241 € 175,412,241 SHARE PRICE SUMMARY 2020 Listing on Frankfurt Stock Exchange (XETRA) High (28 December): € 30.30 Low (12 March): € 18.69 Opening Price: € 23.79 Closing Price: € 30.28 Weighted average number of shares outstanding: 165,110,695 Total number of shares outstanding as at 31 Dec: 165,110,695 Average daily trading volume (all exchanges): 1,466,481 Market capitalisation as at 31 Dec: € 4,963.34 m Earnings per share (diluted/basic): € 0.04/€ 0.04 Dividend per share: € 0.00 Expand table LISTING ON NASDAQ Since November 2021 Evotec SE is listed on NASDAQ (Ticker Symbol: EVO). Please find all further information regarding the NASDAQ listing as well as al published filings of Evotec SE under the following link: Link to SEC/EDGAR STOCK PRICE & CHART SHAREHOLDER STRUCTURE On 15 November 2021, the number of total voting rights amounts to 175,412,241. Under the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG), shareholders of a listed German company are required to notify the Company and the German Federal Financial Supervisory Authority (BaFin) of any change to the voting interest in Evotec SE whenever it reaches, exceeds or falls below specified thresholds (3%, 5%, 10%, 15%, 20%, 25%, 30%, 50% or 75% of the voting rights). Evotec’s voting rights announcements can be found at dgap.de. Three shareholders, Novo Holdings A/S, T. Rowe Price Group Inc. and Mubadala Investment Company, currently hold more than 5% of the shares of Evotec SE. The free float according to the definition of the Frankfurt Stock Exchange is approx. 68% according to our estimates (Evotec: 11|2021). Shareholder structure (in %)* * Rounding differences may occur. ANALYSTS Overview of analysts covering the Evotec share Citigroup Inc. Peter Verdult Deutsche Bank Falko Friedrichs FMR Frankfurt Main Research Dr Mohamad Vaseghi goetzpartners securities Limited Dr Chris Redhead Intron Health Naresh Chouhan Kempen & Co. N.V. Alexandru Cogut Stifel Europe Bank Dr Marcus Wieprecht Royal Bank of Canada (RBC) Charles Weston Rx Securities Dr Samir Devani Warburg Research Dr Christian Ehmann Citigroup Inc. Peter Verdult One Court Square, 45th Floor, Long Island City, New York 11120, USA Contact peter.verdult@citi.com vCard LATEST ANALYST RECOMMENDATIONS Below you will find the latest analyst recommendations. Analyst Recommendation Target Price Date of the latest Research Report Citigroup Inc. BUY 29.50 EUR 1 September 2020 Deutsche Bank HOLD 38.00 EUR 16 August 2021 Frankfurt Main Research (FMR) BUY 36.50 EUR 3 February 2021 goetzpartners securities Limited OUTPERFORM 40.00 EUR 20 May 2021 Intron Health BUY 30.00 EUR 13 October 2020 Kempen & Co. N.V. BUY 40.00 EUR 11 May 2021 Stifel Europe Bank HOLD 38.50 EUR 15 July 2021 Royal Bank of Canada (RBC) OUTPERFORM 39.00 EUR 11 May 2021 Rx Securities BUY 50.00 EUR 26 October 2021 Warburg Research BUY 48.00 EUR 27 October 2021 Average Target Price 38.95 EUR CURRENT ANALYST CONSENSUS (HALF-YEAR 2021) DOWNLOADS Analyst consensus H1 2021 XLSX, 55.0 KB Important Notice: Evotec is covered and evaluated by the analysts mentioned above. Please note that any opinions, estimates or forecasts regarding Evotec's performance made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Evotec or its management. The above reference to the analysts does not imply that Evotec endorses their opinions. Evotec is under no obligation to update or supplement the information provided above and does not guarantee the accuracy or completeness of this list. Copies of the reports from the analysts listed above can be obtained directly from the analysts or their employers. Due to legal requirements Evotec is not allowed to publish the analyst reports. EVOTEC'S DIVIDEND POLICY The payment of dividends depends on Evotec’s financial situation and liquidity requirements, general market conditions, and statutory, tax and regulatory requirements. Evotec has never paid or declared any cash dividends on its ordinary shares, and does not anticipate paying any cash dividends on its ordinary shares in the foreseeable future. Evotec intends to retain all available funds and any future earnings and reinvest them in the company’s further growth strategy to better leverage longterm growth and sustainability. Under German law, Evotec may pay dividends only from the distributable profit (Bilanzgewinn) reflected in its unconsolidated financial statements (as opposed to the consolidated financial statements for Evotec and its subsidiaries) prepared in accordance with the principles set forth in the German Commercial Code (Handelsgesetzbuch) and adopted by the Evotec Management Board (Vorstand) and the Supervisory Board (Aufsichtsrat), or, as the case may be, by the shareholders of Evotec in a general shareholders’ meeting. In addition, under German law Evotec may not pay dividends before annual profits exceed the losses carried forward. All of the shares represented by the ADSs offered in USA generally have the same dividend rights as all of Evotec's other outstanding shares. Thursday, November 25th 2021 Previous Next 1 °C Orth/Donau Imprint Privacy Policy Legal notice T&Cs RSS RSS Twitter LinkedIn EVOTEC @Evotec Our presentation at #EBF2021 is today at 17:00 CET | Quantification of two mAbs using both ELISA and LC-MS/MS gener… https://t.co/M5X67v2V5J 11:10 AM - 25 NOVEMBER 2021